Background Only a few recent phase III trials with targeted therapies or immune checkpoint
inhibitors (ICIs) in metastatic clear-cell renal cell carcinoma (m-ccRCC) demonstrated an …

Introduction The aim of this retrospective clinical study was to assess, in the context of the
recent evolution of systemic therapies, the potential effect of targeted therapies on overall …

Introduction Because the treatment landscape for metastatic renal cell carcinoma (mRCC)
has evolved dramatically over the past decade, data on patients' treatment and outcomes in …

Opinion statement Treatment of metastatic clear cell renal cancer (mccRCC) has seen
substantial progress over the last 20 years, with many regulatory approvals since 2006 …

Background The treatment landscape of metastatic clear cell renal cell carcinoma (mccRCC)
has been transformed by targeted therapies with tyrosine kinase inhibitors (TKI) and more …

Background: About 40% of metastatic clear-cell renal cell carcinoma (m-ccRCC) patients
receive a second-line targeted therapy after failure of anti-vascular endothelial growth factor …

Simple Summary First-line treatment options for metastatic clear cell renal cell carcinoma
have significantly increased. The current recommended therapeutic strategy is based on a …

PURPOSE To provide recommendations for the management of patients with metastatic
clear cell renal cell carcinoma (ccRCC). METHODS An Expert Panel conducted a systematic …

The treatment of metastatic clear-cell renal cell cancer (mccRCC) has seen substantial
progress over the last decade. Until 2006, non-specific immunotherapy with high dose …

Abstract Treatment paradigm for metastatic clear cell renal cell carcinoma (mccRCC) has
changed dramatically over the recent decades. From cytokines, interleukin-2 and interferon …